# Ayuh Ventures

> Ayuh Ventures invests in healthcare technology, with disclosed exposure to neuroscience, therapeutics, medical devices and drug-discovery tools. Its portfolio includes companies developing treatments and technologies for mental health, women's health and other underserved clinical needs.

## Profile

- **Stage-based planning range:** $250K–$3M
- **Check-size evidence basis:** estimated
- **Founded:** 2021
- **Headquarters:** New York City, New York, United States
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** Pre-Seed, Seed, Series B
- **Last verified:** 2026-11-15

## Links

- [Website](https://www.ayuhvc.com/)
- [LinkedIn](https://www.linkedin.com/company/ayuh-ventures)

## In-depth investment analysis

## What does Ayuh Ventures invest in?

Ayuh Ventures is a New York healthcare investor with a portfolio spanning neuroscience, therapeutics, medical devices and drug-discovery tools. Its [official website](https://www.ayuhvc.com/) highlights [Samphire Neuroscience](/startup/samphire-neuroscience), [Gilgamesh Pharmaceuticals](/startup/gilgamesh-pharmaceuticals) and [Beckley Psytech](/startup/beckley-psytech).

These are different routes to improving health: a wearable device, a drug-development platform and a clinical-stage therapeutic business. The common thread is healthcare technology, rather than a single treatment format.

## Which founders should consider Ayuh?

Founders developing neuroscience, mental-health, medical-device or therapeutic technologies have the clearest connection to its disclosed portfolio. Historical investments also include women's health, sexual health and drug-discovery platforms.

A useful introduction should make the scientific claim, validation achieved, next development milestone and route to customers or patients easy to understand. Clinical evidence, regulatory planning, intellectual property and financing needs matter differently for a device, a discovery platform and a drug candidate. This is preparation guidance based on the portfolio, not a firm-issued application rubric.

## Investment stages and check size

Ayuh's historical reporting includes pre-seed, seed and Series B participation, with investments through both a fund and SPVs. A later-stage investment does not establish that the firm currently has a general later-stage mandate.

A standard current check range is not independently established here. Founders should confirm the individual investment size, lead or participant role, follow-on capacity and investing vehicle directly with the team.

## Selected portfolio companies

| Company | Business | Context |
|---|---|---|
| [Samphire Neuroscience](/startup/samphire-neuroscience) | Wearable neurotechnology for women's health | Ayuh is named in its 2024 pre-seed and 2025 seed financing coverage. |
| [Gilgamesh Pharmaceuticals](/startup/gilgamesh-pharmaceuticals) | Neuropsychiatric drug development | AbbVie completed the acquisition of its bretisilocin asset in October 2025; this is not evidence that every Gilgamesh program was acquired. |
| [Beckley Psytech](/startup/beckley-psytech) | Clinical-stage mental-health therapeutics | Atai completed the acquisition of the remaining Beckley shares in November 2025. |

The transaction context matters: a historical portfolio company may subsequently sell an asset or become part of another business. Neither outcome, by itself, discloses Ayuh's realized proceeds or fund returns.

## Documented funding-round participation

| Company | Financing | Public round size | Evidence |
|---|---|---|---|
| [Samphire Neuroscience](/startup/samphire-neuroscience) | Pre-seed; February 2024 | $2.3M total round | [FIRSTPICK's published coverage](https://firstpick.vc/blog/samphire-neuroscience-is-building-a-brain-stimulating-wearable-for-period-pain/) names Ayuh among investors. |
| [Samphire Neuroscience](/startup/samphire-neuroscience) | Seed; announced June 3, 2025 | $5M total round | [Financing announcement](https://paaomasijoittajat.fi/en/ajankohtaista/news/30188/samphire-neuroscience-raises-5-million-seed-round-to-advance-breakthrough-neurotechnology-for-womens-health/) names Ayuh among returning investors. |

The 2025 round was co-led by Fortify Ventures and Inventure. Ayuh's individual contribution is undisclosed. Public sources use different announcement dates; VCT uses the dated announcements attached to the records, not an assumed legal closing date.

## Publicly identified portfolio

The table combines the firm's website, its indexed AngelList portfolio and Kunal Sethi's historical [2022 longevity fund report](https://numberoneksvc.medium.com/our-2022-longevity-fund-annual-report-196c61757479). The report's original page is intermittently inaccessible; its indexed extracts provide historical context, not a current ownership register.

| Company | Investment record |
|---|---|
| Beckley Psytech | Manager reports a 2021 Series B investment; also named on Ayuh's website. |
| Clerkenwell Health | Manager reports a March 2022 Pre-Seed+ investment. |
| Gilgamesh Pharmaceuticals | Manager reports Series B participation in May 2022; also on Ayuh's website. |
| Kadence Bio, formerly Kanna Health | Manager reports June 2022 Pre-Seed+ participation under the former name. |
| Samphire Neuroscience | Manager reports April and August 2022 investments; later rounds documented above. |
| Lief Therapeutics | Manager reports a 2021 SPV investment and a Fund I Seed+ follow-on. |
| Pepper Bio | Manager reports a June 2022 seed investment. |
| Psy Therapeutics | Manager reports April 2022 Seed+ participation. |
| Mindstate Design Labs | Named in Ayuh's indexed AngelList portfolio. |
| Reset Pharmaceuticals | Listed by investment databases, including [aVenture](https://aventure.vc/investors/firms/ayuh-ventures-brooklyn-ny-us/portfolio); precise entry-round attribution needs primary confirmation. |

[AngelList's indexed portfolio](https://venture.angellist.com/v/ayuh/syndicate) corroborates several of these names. Kanna Health [rebranded to Kadence Bio](https://www.kadencebio.com/news/kanna-health-is-now-kadence-bio); they should not be counted as two investments.

## Team and relationship with Prithvi Ventures

**Kunal Sethi is General Partner**, while **Murali Sethumadhavan is Operating Partner**. Their involvement is supported by [Prithvi's official team biographies](https://www.prithvivc.com/team) and [Ayuh's company profile](https://www.linkedin.com/company/ayuh-ventures).

They also work with [Prithvi Ventures](/fund/prithvi-ventures), which concentrates on energy and industrial technology. The shared team is useful context, but each investment should be attributed to the firm or vehicle identified in its source.

## How to explore further

Visit [Ayuh's official website](https://www.ayuhvc.com/) for its current positioning. Compare it with other investors in the [New York hub](/vc/new-york) and [NYC early-stage directory](/nyc-early-stage-seed-firms-2025).

For current corporate status, the strongest sources are [AbbVie's completed bretisilocin transaction](https://news.abbvie.com/2025-10-17-AbbVie-Completes-Acquisition-of-Gilgamesh-Pharmaceuticals-Bretisilocin) and [Atai's Beckley acquisition filing](https://ir.atai.com/static-files/284c58df-b2ca-4bb6-a582-34239a9a82e1). They establish what changed at the portfolio companies, not a return multiple for Ayuh.

## Research sources

- [Official website and selected portfolio](https://www.ayuhvc.com/)
- [Shared team biographies](https://www.prithvivc.com/team)
- [Ayuh company profile](https://www.linkedin.com/company/ayuh-ventures)
- [Samphire 2024 financing: investor coverage](https://firstpick.vc/blog/samphire-neuroscience-is-building-a-brain-stimulating-wearable-for-period-pain/)
- [Samphire 2025 seed announcement](https://paaomasijoittajat.fi/en/ajankohtaista/news/30188/samphire-neuroscience-raises-5-million-seed-round-to-advance-breakthrough-neurotechnology-for-womens-health/)
- [Historical 2022 manager report (indexed)](https://numberoneksvc.medium.com/our-2022-longevity-fund-annual-report-196c61757479)
- [Atai completion filing](https://ir.atai.com/static-files/284c58df-b2ca-4bb6-a582-34239a9a82e1)
- [AbbVie asset acquisition completion](https://news.abbvie.com/2025-10-17-AbbVie-Completes-Acquisition-of-Gilgamesh-Pharmaceuticals-Bretisilocin)

## Questions and answers

### What does Ayuh Ventures invest in?

Healthcare, including neuroscience, mental-health therapeutics, medical devices and drug-discovery platforms. Its historical portfolio also includes women's and sexual health technologies.

### Where is Ayuh Ventures based?

New York City, according to its company profile.

### Who are Ayuh Ventures' team members?

Kunal Sethi is General Partner and Murali Sethumadhavan is Operating Partner. Both also work with Prithvi Ventures.

### What is Ayuh Ventures' check size?

A current standard range has not been independently established. Founders should confirm investment size and vehicle directly with the firm.

### Did Ayuh invest $5 million in Samphire?

The $5 million figure is Samphire Neuroscience's entire 2025 seed round. Ayuh was named among returning participants; its individual contribution was not disclosed.

**Research verified:** 2026-11-15

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/ayuh-ventures
